Aliases & Classifications for Somatization Disorder

Aliases & Descriptions for Somatization Disorder:

Name: Somatization Disorder 12 14 69
Polysomatising Disorder 12
Somatisation Disorder 12
Somatoform Disorders 42
Somatoform Disorder 69
Briquet's Disorder 12

Classifications:



External Ids:

Disease Ontology 12 DOID:13918
ICD10 33 F45.0 F45 F45.9
ICD9CM 35 300.81
MeSH 42 D013001
UMLS 69 C0520482

Summaries for Somatization Disorder

Disease Ontology : 12 A somatoform disorder that involves persistently complaints of varied physical symptoms that have no identifiable physical origin.

MalaCards based summary : Somatization Disorder, also known as polysomatising disorder, is related to somatoform disorder and personality disorder, and has symptoms including multiple somatic complaints An important gene associated with Somatization Disorder is DCXR (Dicarbonyl And L-Xylulose Reductase), and among its related pathways/superpathways are Jak-STAT signaling pathway (KEGG) and Signaling pathways regulating pluripotency of stem cells. The drugs Citalopram and Pregabalin have been mentioned in the context of this disorder. Affiliated tissues include testes, brain and pituitary, and related phenotype is Increased HDAC inhibitor resistance.

Wikipedia : 71 Somatization disorder (also Briquet\'s syndrome) was a mental disorder characterized by recurring,... more...

Related Diseases for Somatization Disorder

Graphical network of the top 20 diseases related to Somatization Disorder:



Diseases related to Somatization Disorder

Symptoms & Phenotypes for Somatization Disorder

UMLS symptoms related to Somatization Disorder:


multiple somatic complaints

GenomeRNAi Phenotypes related to Somatization Disorder according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased HDAC inhibitor resistance GR00115-A-0 8.62 LIF LIFR

Drugs & Therapeutics for Somatization Disorder

Drugs for Somatization Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 222)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Citalopram Approved Phase 4,Phase 3 59729-33-8 2771
2
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3 148553-50-8 5486971
3
Triamcinolone Approved, Vet_approved Phase 4,Phase 3 124-94-7 31307
4 Piracetam Approved Phase 4 7491-74-9
5
Fluoxetine Approved, Vet_approved Phase 4,Phase 1,Phase 2 54910-89-3 3386
6
Acetaminophen Approved Phase 4 103-90-2 1983
7
Cycloserine Approved Phase 4,Early Phase 1 68-41-7 401 6234
8
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
9
Lidocaine Approved, Vet_approved Phase 4,Phase 2 137-58-6 3676
10
Sertraline Approved Phase 4 79617-96-2 68617
11
Dopamine Approved Phase 4,Phase 3 51-61-6, 62-31-7 681
12
Norepinephrine Approved Phase 4,Phase 3 51-41-2 439260
13
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
14
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
15
Olanzapine Approved, Investigational Phase 4,Phase 3 132539-06-1 4585
16
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Early Phase 1 51-84-3 187
17
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
18
Flunarizine Approved Phase 4 52468-60-7 941361
19
Histamine Approved, Investigational Phase 4 75614-87-8, 51-45-6 774
20
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
21
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
22
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
23
decanoic acid Experimental Phase 4 334-48-5 2969
24 Anticoagulants Phase 4,Phase 2
25 Pentosan Sulfuric Polyester Phase 4
26 Anticonvulsants Phase 4,Phase 3,Phase 2
27 Antidepressive Agents Phase 4,Phase 3,Phase 2,Phase 1
28 Antidepressive Agents, Second-Generation Phase 4,Phase 3,Phase 1,Phase 2
29 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
30 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
31 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1
32
Serotonin Phase 4,Phase 3,Phase 1,Phase 2 50-67-9 5202
33 Serotonin Agents Phase 4,Phase 3,Phase 1,Phase 2
34 Serotonin Uptake Inhibitors Phase 4,Phase 3,Phase 1,Phase 2
35 Anesthetics Phase 4,Phase 3,Phase 2
36 Anesthetics, Local Phase 4,Phase 3,Phase 2
37 Anti-Arrhythmia Agents Phase 4,Phase 2
38 Central Nervous System Depressants Phase 4,Phase 3,Phase 2
39 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
40 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
41 Antipsychotic Agents Phase 4,Phase 3
42 Tranquilizing Agents Phase 4,Phase 3
43 Antiparkinson Agents Phase 4,Phase 3
44 Autonomic Agents Phase 4,Phase 3
45 Cholinergic Agents Phase 4,Phase 3,Phase 2,Early Phase 1
46 Cholinergic Antagonists Phase 4,Phase 3
47 Muscarinic Antagonists Phase 4,Phase 3
48 Parasympatholytics Phase 4,Phase 3
49 Anti-Anxiety Agents Phase 4,Phase 3
50 calcium channel blockers Phase 4,Phase 3

Interventional clinical trials:

(show top 50) (show all 269)
id Name Status NCT ID Phase
1 Efficacy Study of Pentosan Polysulfate Sodium,Hydrodistension and Combination Therapy for Bladder Pain Syndrome Unknown status NCT01895153 Phase 4
2 Effectiveness of Levetiracetam in the Treatment of Body Dysmorphic Disorder Completed NCT00265109 Phase 4
3 Fluoxetine in Pediatric Body Dysmorphic Disorder Completed NCT00245635 Phase 4
4 Treating Urological Chronic Pelvic Pain Syndrome (UCPPS) Pain Completed NCT02385266 Phase 4
5 Lansoprazole Versus Mosapride for Functional Dyspepsia Completed NCT00663897 Phase 4
6 Treatment of Myofascial Pain Syndrome With Lidocaine Injection and Physical Therapy. Completed NCT01250184 Phase 4
7 Treatments for Psychogenic Nonepileptic Seizures (NES) Completed NCT00159965 Phase 4
8 Treatment Trial for Psychogenic Nonepileptic Seizures Completed NCT00835627 Phase 4
9 Primary Care Intervention Strategy for Anxiety Disorders Completed NCT00347269 Phase 4
10 Open Trial of Duloxetine in Outpatients With Irritable Bowel Syndrome Symptoms and Co-Morbid Major Depression Completed NCT01754493 Phase 4
11 A Duloxetine Dosing Strategy Study in Korean Patients With Major Depressive Disorder Completed NCT00960986 Phase 4
12 Switching to Duloxetine in Patients With Depression Completed NCT00696774 Phase 4
13 Compliance With Antidepressant Medication in Treatment of Functional Dyspepsia Completed NCT01851863 Phase 4
14 A Study Comparing Duloxetine to Other Antidepressants in the Treatment of Severe Depression Completed NCT00666757 Phase 4
15 Duloxetine Versus Duloxetine Plus Non-Drug Therapy for Depression Completed NCT00494377 Phase 4
16 GRASSP: Gralise® for Spine Surgery Pain Recruiting NCT01764464 Phase 4
17 Neurologic Signatures of Chronic Pain Disorders Recruiting NCT02747940 Phase 4
18 Clinical Trial of Tenoten® in the Treatment of Anxiety in Patients With Somatoform, Stress-related and Other Neurotic Disorders Recruiting NCT03036293 Phase 4
19 Comparison of Venlafaxine and Fluoxetine in the Treatment of Postmenopausal Women With Major Depression Recruiting NCT01824433 Phase 4
20 Assessment of Adverse Events in a Naive Pediatric Population Treated With an Antipsychotic Active, not recruiting NCT02007928 Phase 4
21 CBT as an Adjunct to SRIs in the Treatment of BDD Terminated NCT00211809 Phase 4
22 Botox as a Treatment for Chronic Male Pelvic Pain Syndrome Terminated NCT00194623 Phase 4
23 Chronic Bladder Pain Syndrome in Women: Can Doxycycline Help? A Prospective Study Terminated NCT01879930 Phase 4
24 Using Saline for Myofascial Pain Syndromes (USAMPS) Terminated NCT02120261 Phase 4
25 Examination of Pregabalin Access for Treatment of Indicated Pain Disorders: the ExPAND Study Terminated NCT01280747 Phase 4
26 Autonomic Dysfunction and Spinal Cord Stimulation in Complex Regional Pain Syndrome Terminated NCT00780390 Phase 4
27 Sinusitis and Facial Pain Disorders Anti-Depression Trial Terminated NCT00754793 Phase 4
28 Comparative Study of Epigastric Pain Syndrome and Postprandial Distress Syndrome Withdrawn NCT00673972 Phase 4
29 Intravenous Immunoglobulins in Complex-regional Pain Syndrome Unknown status NCT00949065 Phase 3
30 RCT :Thoracic Sympathetic Block for the Treatment of Complex Regional Pain Syndrome I of the Upper Limb Unknown status NCT01612364 Phase 3
31 Analysis of Photoplethysmographic Signal in Lumbar Sympathetic Block Unknown status NCT01134289 Phase 3
32 Efficacy & Safety Study of Pregabalin to Treat Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) Unknown status NCT00371033 Phase 3
33 Psychological Prevention of Internalizing Disorders Unknown status NCT00564239 Phase 3
34 DEPENAS: A Psychosocial Intervention for Patients With Medically Unexplained Symptoms Completed NCT00130988 Phase 3
35 Treatment of Medically Unexplained Physical Ailments (Somatization Disorder) Completed NCT00050583 Phase 3
36 Comparing Cognitive Therapy and Exposure Therapy in Individuals With Hypochondriasis Completed NCT01119469 Phase 3
37 Integrated Treatment Program for Hypochondriasis in Primary Care Settings Completed NCT00368212 Phase 3
38 Effectiveness of Escitalopram in the Treatment of Body Dysmorphic Disorder Completed NCT00149799 Phase 3
39 Treatment of Patients With Longstanding Unexplained Health Complaints Completed NCT00132197 Phase 2, Phase 3
40 Prevalence of Salivary Hypofunction in Patients With Globus Pharyngeus Completed NCT00381771 Phase 2, Phase 3
41 Diacutaneous Fibrolysis and Patellofemoral Pain Syndrome Completed NCT02379364 Phase 3
42 Biofeedback-Based Cognitive Behavioral Treatment for Temporomandibular Disorders Completed NCT00769561 Phase 2, Phase 3
43 A Study of the Combination of Electrical Stimulation and Dysport® in Myofascial Pain Syndrome. Completed NCT00246142 Phase 3
44 Pain Exposure Physical Therapy (PEPT) Versus CBO in Patients With Complex Regional Pain Syndrome Type I (CRPS-1) Completed NCT00817128 Phase 2, Phase 3
45 A Study of the Effect of Lenalidamide on Complex Regional Pain Syndrome Type 1 Completed NCT00166452 Phase 3
46 Efficacy Study of a Standardized Pollen Extract Preparation (Cernilton) to Treat Inflammatory Chronic Prostatitis-Chronic Pelvic Pain Syndrome (CP-CPPS) Completed NCT00919893 Phase 3
47 A Confirmatory Study of Fentanyl in Participants With Post-herpetic Neuralgia, Complex Regional Pain Syndrome or Postoperative Pain Syndrome Completed NCT01008553 Phase 3
48 Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder Completed NCT00105989 Phase 3
49 Study to Evaluate the Efficacy, Safety and Tolerability of Bupropion Hydrochloride Extended-release Tablet, and Escitalopram Oxalate Capsule in Subjects With Major Depressive Disorder Completed NCT02191397 Phase 3
50 A Six-Week Study Evaluating The Efficacy And Safety Of Geodon In Patients With A Diagnosis Of Bipolar I Depression Completed NCT00141271 Phase 3

Search NIH Clinical Center for Somatization Disorder

Cochrane evidence based reviews: somatoform disorders

Genetic Tests for Somatization Disorder

Anatomical Context for Somatization Disorder

MalaCards organs/tissues related to Somatization Disorder:

39
Testes, Brain, Pituitary

Publications for Somatization Disorder

Articles related to Somatization Disorder:

(show top 50) (show all 160)
id Title Authors Year
1
Clinical significance of increased cerebellar default-mode network connectivity in resting-state patients with drug-naive somatization disorder. ( 27428190 )
2016
2
Decreased interhemispheric functional connectivity in insula and angular gyrus/supramarginal gyrus: Significant findings in first-episode, drug-naive somatization disorder. ( 26826895 )
2016
3
Decreased Plasma BDNF Levels of Patients with Somatization Disorder. ( 27757131 )
2016
4
Abnormal default-mode network homogeneity and its correlations with personality in drug-naive somatization disorder at rest. ( 26771948 )
2016
5
Alterations in white matter integrity in first-episode, treatment-naive patients with somatization disorder. ( 26003450 )
2015
6
Abnormal regional homogeneity and its correlations with personality in first-episode, treatment-naive somatization disorder. ( 26026373 )
2015
7
Trauma-related psychiatric comorbidity of somatization disorder among women in eastern Turkey. ( 25214370 )
2014
8
Increased functional connectivity strength of right inferior temporal gyrus in first-episode, drug-naive somatization disorder. ( 25313257 )
2014
9
A study of disability and its correlates in somatization disorder. ( 24655628 )
2014
10
Dissociation of regional activity in default mode network in medication-naive, first-episode somatization disorder. ( 24983962 )
2014
11
SYMPTOMATOLOGY AND COMORBIDITY OF SOMATIZATION DISORDER AMONGST GENERAL OUTPATIENTS ATTENDING A FAMILY MEDICINE CLINIC IN SOUTH WEST NIGERIA. ( 26069465 )
2014
12
Caregiver burden and disability in somatization disorder. ( 24119946 )
2013
13
Effectiveness of group versus individual cognitive-behavioral therapy in patients with abridged somatization disorder: a randomized controlled trial. ( 23788694 )
2013
14
Mindfulness therapy for somatization disorder and functional somatic syndromes: analysis of economic consequences alongside a randomized trial. ( 23272987 )
2013
15
Mindfulness therapy for somatization disorder and functional somatic syndromes: randomized trial with one-year follow-up. ( 23272986 )
2013
16
Brain dysfunction in fibromyalgia and somatization disorder using proton magnetic resonance spectroscopy: a controlled study. ( 22211322 )
2012
17
Pituitary volumes are reduced in patients with somatization disorder. ( 22993528 )
2012
18
Phase II trial on the effects of Silexan in patients with neurasthenia, post-traumatic stress disorder or somatization disorder. ( 22475718 )
2012
19
The association between Helicobacter Pylori chronic gastritis, psychological trauma and somatization disorder. A case report. ( 21961102 )
2011
20
Somatization disorder treated with electroconvulsive therapy. ( 21865963 )
2011
21
Hippocampus and amygdalar volumes in patients with somatization disorder. ( 21651951 )
2011
22
From traumatic attachment to somatization disorder. ( 21995353 )
2011
23
Perceived social support and life satisfaction in persons with somatization disorder. ( 22174534 )
2010
24
Glucocorticoid signaling in the cell. Expanding clinical implications to complex human behavioral and somatic disorders. ( 19906238 )
2009
25
C-reactive protein variations for different chronic somatic disorders. ( 19372230 )
2009
26
Is baroreflex sensitivity really pathological in patients with somatization disorder? Comment on: Laederach-Hofmann et al. (2008). ( 19505528 )
2009
27
Complex post-traumatic stress disorder in patients with somatization disorder. ( 19085532 )
2009
28
Cognitive-affective neuroscience of somatization disorder and functional somatic syndromes: reconceptualizing the triad of depression-anxiety-somatic symptoms. ( 18496475 )
2008
29
Managing somatization disorder. ( 23212087 )
2008
30
Are patients with somatization disorder highly suggestible? ( 18028249 )
2008
31
Childhood maltreatment in patients with somatization disorder. ( 18330776 )
2008
32
Cognitive-behaviour therapy for patients with Abridged Somatization Disorder (SSI 4,6) in primary care: a randomized, controlled study. ( 18570681 )
2008
33
Somatization disorder, a cause of difficult pain: a case report. ( 17601846 )
2007
34
P300 endogen evoked potentials in somatization disorder: a controlled study. ( 17323226 )
2007
35
Temperament profiles in women with somatization disorder. ( 17875043 )
2007
36
Vulvodynia as a possible somatization disorder. More than just an opinion. ( 17393771 )
2007
37
Personality disorders in somatization disorder patients: a controlled study in Spain. ( 17540225 )
2007
38
Cognitive-behavioral therapy for somatization disorder: a randomized controlled trial. ( 16864762 )
2006
39
Distinguishing between hypochondriasis and somatization disorder: a review of the existing literature. ( 16899963 )
2006
40
Dissociation, childhood interpersonal trauma, and family functioning in patients with somatization disorder. ( 15863791 )
2005
41
Somatization disorder in young adult population. ( 14757296 )
2004
42
Somatization disorder and cancer: a case history and review. ( 16594404 )
2004
43
Suicide risk in patients with somatization disorder. ( 15384650 )
2004
44
The presentation of irritable bowel syndrome in the context of somatization disorder. ( 15354279 )
2004
45
Episodic ataxia vs somatization disorder. ( 15633862 )
2004
46
Volumes of the caudate nuclei in women with somatization disorder and healthy women. ( 15246456 )
2004
47
Somatization disorder--a defensive waste of NHS resources. ( 15103033 )
2004
48
Somatization disorder: a practical review. ( 15560311 )
2004
49
Bright-light therapy in somatization disorder. ( 12655916 )
2003
50
Somatization disorder and bradykinin. ( 14629712 )
2003

Variations for Somatization Disorder

Expression for Somatization Disorder

Search GEO for disease gene expression data for Somatization Disorder.

Pathways for Somatization Disorder

GO Terms for Somatization Disorder

Biological processes related to Somatization Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 response to cytokine GO:0034097 9.26 LIFR SCGB1A1
2 embryo implantation GO:0007566 9.16 LIF SCGB1A1
3 regulation of cell differentiation GO:0045595 8.96 LIF SIK1
4 leukemia inhibitory factor signaling pathway GO:0048861 8.62 LIF LIFR

Sources for Somatization Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....